Metabolomics Services Market Size to Exceed US$ 7.31 Bn by 2032

The Metabolomics Services Market, estimated at US$ 3.21 Bn in 2025, is expected to exhibit a CAGR of 12.5% and reach US$ 7.31 Bn by 2032.

The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.

Market Dynamics:

Rising focus on personalized medicine and growing prevalence of chronic diseases such as cancer are the major drivers propelling the demand for metabolomics services. According to the World Health Organization, chronic diseases accounted for 71% of global deaths in 2025. Metabolomics helps in better understanding disease mechanisms and improving diagnostics of chronic conditions. This is increasing the application of metabolomics in therapeutics development and precision medicine initiatives. Furthermore, technological advancements in metabolomics platforms such as mass spectrometry and nuclear magnetic resonance spectroscopy (NMR) are enabling high-throughput analysis of metabolites. Cell and animal metabolomics services are also gaining traction in preclinical drug research. Improved cost-efficiency of metabolomics relative to genomics and proteomics is further supporting the market growth.

Increasing Research Funding and Government Support is Driving Growth in the Global Metabolomics Services Market

Government and private funding for life sciences research have increased significantly in recent years. Metabolomics research is gaining substantial funding as it can provide insights for disease diagnosis, drug discovery, and many other healthcare applications. For example, the National Institutes of Health (NIH) doubled its funding for metabolomics research between 2010 and 2015 to over US$ 150 million per year. This increase in dedicated funding is allowing more researchers and organizations to utilize metabolomics services which is driving higher demand. Government agencies are also introducing initiatives and guidelines to support metabolomics research. For instance, the U.S Food and Drug Administration (FDA) published guidance on metabolomics data submission for regulatory purposes in 2025. Such regulatory developments help standardize methods and validate results which makes metabolomics more approachable for pharmaceutical and biotech applications. The increased research support and standardized frameworks are encouraging the commercialization of metabolomics, thereby propelling the global metabolomics services market.

Advancements in Omics Technologies are Enabling Wider Adoption of Metabolomics

Rapid technological progress is making omics techniques like metabolomics more effective and affordable. Next-generation mass spectrometry and NMR instruments provide higher resolution data at lower costs. Improved bioinformatics tools are enabling more comprehensive metabolite identification and pathway analysis from large datasets. Artificial intelligence and machine learning algorithms are automating data processing workflows. Companies are integrating multi-omics approaches to gain a more holistic view of biological systems. For example, combining genomics, proteomics, and metabolomics can help discover novel disease biomarkers. The advancements in related fields are lowering the technical barriers for metabolomics adoption. Researchers can now leverage metabolomics alongside other omics to answer complex questions in areas like precision medicine. This is increasing the utility of metabolomics services and driving the market growth.

Limited Availability of Skilled Professionals Restrains Market Growth

While the interest in metabolomics is growing rapidly, there remains a severe shortage of trained and experienced researchers and data analysts with metabolomics expertise. Metabolomics projects involve highly specialized instrumentation, analytical techniques and bioinformatics which require years of training. Although universities are introducing dedicated metabolomics courses, the specialized talent pool remains small relative to demand. Service providers struggle to hire qualified staff who can perform complex studies, analyze large datasets and provide effective consultations to clients. The technical complexity and multi-disciplinary nature of metabolomics means full-scale metabolite identification and quantitation still needs significant human oversight, limiting automation. The shortage of skilled labor increases project costs and timelines, hampering the scale-up of metabolomics activities. It also discourages smaller labs and startup companies from entering the space. This talent crunch remains a major challenge restraining faster growth of the global metabolomics services industry.

Emergence of Personalized Medicine is Opening New Avenues

Personalized or precision medicine aims to tailor medical treatment to individual characteristics, needs and preferences. It relies on understanding how a person's genes, environment, and lifestyle influence health on a molecular level. Metabolomics plays a critical role here by providing insight into small molecule signatures and pathways. Monitoring an individual's metabolome over time can help detect diseases early, track treatment progress, prevent adverse reactions and optimize therapies. Several pharmaceutical companies are partnering with clinical laboratories and diagnostic developers to apply metabolomics approaches for precision oncology, cardiology, neurology and other areas. The global personalized medicine market is expected to reach over US$ 150 billion by 2025. As metabolomics establishes itself as an essential tool, the demand for supporting services from clinical, academic, and industrial players in this high-growth field will also rise substantially. This presents a major opportunity for metabolomics service providers to target personalized and precision medicine applications.

Artificial Intelligence and Automation Can Enhance Market Accessibility

While metabolomics requires experienced researchers currently, AI and machine learning have the potential to reduce dependency on specialized human labor over time. Deep learning algorithms can automate tasks like compound identification from spectral data, metabolite quantification, biomarker discovery and pathway mapping at a scale and speed not possible manually. Cloud-based ‘omics platforms with integrated AI are emerging that democratize techniques like metabolomics for non-expert users. AI assistants can guide experimental design, perform multi-omics integration, generate extensive reports, and manage projects end-to-end with minimal human oversight. This will make omics techniques more scalable and affordable for smaller labs, biobanks and clinical sites globally. The increased accessibility could significantly expand the client base for commercial metabolomics service providers. AI/ML is also enhancing data analytics, enabling new applications and discoveries that will fuel further innovation and investment in this area over the long run.

Link: https://www.coherentmarketinsights.com/market-insight/metabolomics-market-180

Key Developments:

• On May 30, 2024, Metabolon, Inc., a leader in metabolomics solutions, launched a 4-week turnaround for Global Discovery Panel projects handling up to 2,000 samples. This initiative caters to the needs of the commercial pharmaceutical sector by accelerating R&D through timely insights from biological samples such as plasma, urine, and serum.
• On January 26, 2023, CosmosID, a leader in high-resolution microbiome analysis, introduced metabolomics services to enhance multi-omics research. By integrating metagenomics, metatranscriptomics, and metabolomics, the service provides comprehensive insights into microbial composition, gene expression, and metabolite production, offering actionable data for microbiome advancements.
• In July 2021, Thermo Fisher Scientific, a global leader in scientific innovation, partnered with University of California to establish the Center of Excellence in Clinical Metabolomics. This collaboration aims to drive advancements and standardization in metabolomics research.
• In April 2021, BioMérieux, a pioneer in in-vitro diagnostics specializing in microbiology, immunology, and molecular diagnostics, received CE Marking for its VITEK MS PRIME system. This state-of-the-art MALDI-TOF mass spectrometry platform enhances rapid microorganism identification and optimizes microbiology workflows.

Key Players:

Agilent Technologies, Thermo Fisher Scientific, Waters Corporation, Bruker Corporation, Merck KGaA, PerkinElmer, Danaher Corporation, Bio-Rad Laboratories, Shimadzu Corporation, Human Metabolome Technologies, Inc., Metabolon, Inc., LECO Corporation, Scion Instruments, DANI Instruments S.p.A., and GL Sciences.